

Kidney, Bladder and Testes DOG Meeting

Draft Agenda

May 1, 2010

1300-1430h

Location: TBD

1. A phase I multi-centre study to assess the safety, tolerability, pharmacokinetics and efficacy of the TOR kinase inhibitor AZD8055 in combination with paclitaxel with a randomized phase II expansion to TCC
2. A phase Ib/II multi-centre study of AZD7762 in combination with gemcitabine and cisplatin for advanced urothelial carcinomas